|
|
|
| Effect of Concurrent Chemoradiotherapy with Paclitaxel for Injection in the Treatment of Locally Advanced Esophageal Carcinoma in the Elderly |
| YANG Jun, YANG Fan |
| Hai'an Hospital of Traditional Chinese Medicine, Jiangsu Province, Hai'an 226600, China |
|
|
|
|
Abstract Objective: To investigate the effect of simultaneous radiotherapy and chemotherapy of Paclitaxel for Injection in the treatment of locally advanced esophageal carcinoma in the elderly. Method: A total of 100 elderly patients with advanced local esophageal carcinoma admitted to Hai'an Hospital of Traditional Chinese Medicine from February 2019 to February 2022 were selected and divided into a combined group of 50 cases and a conventional group of 50 cases according to random number table method. The conventional group was treated with Fluorouracil (500 mg/m2) and Cisplatin Injection (20 mg/m2) + concurrent radiotherapy, and the combined group was treated with Paclitaxel for Injection (100 mg/m2) on the basis of the control group, 14 days for 1 cycle, 6 cycles. Fasting venous blood was collected before and after treatment, and squamous cell carcinoma antigen (SCCA) and cytokeratin 19 fragment (CYFRA21-1) were compared between the two groups. After 6 cycles of treatment, the objective response rate of the two groups was compared. The occurrence of adverse reactions (general fatigue, nausea and myalgia) was compared between the two groups. Result: After treatment, serum CYFRA21-1 and SCCA levels in two groups were decreased (P<0.05), and the serum CYFRA21-1 and SCCA levels in combined group were lower than those in conventional group (P<0.05). The objective remission rate in combined group (68.00%) was higher than that in conventional group (44.00%), there was statistically significant difference in objective remission rate between the two groups (P<0.05), and the incidence of adverse reactions was 14.00% in the combined group and 12.00% in the conventional group, with no statistically significant difference between the two groups (P>0.05). Conclusion: The effect of concurrent radiotherapy and chemotherapy with Paclitaxel for Injection in the treatment of esophageal cancer is relatively obvious, which can effectively improve the objective remission rate of patients, reduce the level of tumor markers, and will not significantly increase the incidence of adverse reactions in patients, so it can be popularized and applied in the elderly patients with locally advanced esophageal cancer.
|
|
Received: 04 January 2023
|
|
|
|
|
|
|
